Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 603 followers
Latest posts
Last updated 4 days ago
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
3 days ago
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority...
GSK presents latest respiratory research to advance patient care at ATS 2026
8 days ago
Patient preference and adherence research highlight potential of long-acting dosing regimens to...
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
16 days ago
Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial...
GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH
17 days ago
Designations recognise potential for efimosfermin to address significant unmet medical need &amp...
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation
18 days ago
Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio...
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma
24 days ago
As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep...
GSK completes acquisition of 35Pharma Inc.
29 days ago
GSK today announced the completion of its previously announced acquisition of 35Pharma...
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers
about 1 month ago
Promising efficacy and safety profile supports start of five pivotal phase III...
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)
about 1 month ago
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
about 2 months ago
Submission supported by statistically significant and clinically meaningful functional cure rates in...
Exdensur (depemokimab) approved in China for the treatment of severe asthma
about 2 months ago
Exdensur is the first and only ultra-long-acting biologic in China for the...